NCT03539900View on ClinicalTrials.gov

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

April 19, 2022

Study Completion Date

March 22, 2023

Conditions
Binge-Eating Disorder
Interventions
DRUG

Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination

NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.

OTHER

Placebo

Placebo will be inactive and taken daily in pill form.

Trial Locations (1)

06520

Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT03539900 - Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder | Biotech Hunter | Biotech Hunter